Evidence map›Paper›PMID 36324638›Full record

ArticleMolecular genetics and metabolism reports2022

Treatment of CLN1 disease with a blood-brain barrier penetrating lysosomal enzyme.

Andreas Hahn, Yuji Sato, Toshiaki Ikeda, Hiroyuki Sonoda, Mathias Schmidt, Charlotte Pfrimmer, Ruben J Boado, William M Pardridge

Abstract readCase Reports
In one paragraph

Article in Molecular genetics and metabolism reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Antibody-Based Biologics for CNS Disorders.Antibodies (Basel, Switzerland) · 2026
    Review
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Andreas HahnDepartment of Child Neurology, Justus-Liebig University Gießen, Germany.
Yuji SatoJCR Pharmaceuticals, Hyogo, Japan.
Toshiaki IkedaJCR Pharmaceuticals, Hyogo, Japan.
Hiroyuki SonodaJCR Pharmaceuticals, Hyogo, Japan.
Mathias SchmidtJCR Pharmaceuticals, Hyogo, Japan.
Charlotte PfrimmerDepartment of Child Neurology, Justus-Liebig University Gießen, Germany.
Ruben J BoadoUniversity of California, Los Angeles, USA.
William M PardridgeUniversity of California, Los Angeles, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Neuronal ceroid lipofuscinosis type 1(CLN1 disease) is a rare autosomal recessive lysosomal storage disease caused by genetic defects of palmitoyl protein thioesterase-1(

Indexed as

Blood-brain barrierCLN1 diseaseEnzyme replacement therapyNeuronal ceroid lipofuscinosis type 1PPT1

Identifiers

PMID36324638
PMCPMC9618832

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.